Literature DB >> 1955713

Salmonella-specific antibodies in reactive arthritis.

O Mäki-Ikola1, M Leirisalo-Repo, A Kantele, P Toivanen, K Granfors.   

Abstract

The development and persistence of Salmonella-specific serum antibodies of different immunoglobulin classes and subclasses were compared between those who developed reactive arthritis (n = 39) and those who did not (n = 58) after Salmonella infection. Antibodies against lipopolysaccharide and SDS-extract antigen were measured by ELISA. A significant difference was seen between the two patient groups after 4-14 months of follow-up; those with reactive arthritis had higher levels of Salmonella-specific IgM, IgG, and IgA class antibodies than those without arthritis. In the increased antibody response, secretory IgA, IgA1, and IgG2 classes were especially well represented. The persisting antibody response is a common feature in reactive arthritis and supports persistence of the pathogen or its components in the host. The differences observed in antibody profiles between Salmonella- and Yersinia-triggered reactive arthritides suggest certain dissimilarities (e.g., in the location of persisting microbes) in the arthritogenic process due to these two microbes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1955713     DOI: 10.1093/infdis/164.6.1141

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

Review 1.  HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.

Authors:  Inés Colmegna; Raquel Cuchacovich; Luis R Espinoza
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  HLA-B27 modulates the survival of Salmonella enteritidis in transfected L cells, possibly by impaired nitric oxide production.

Authors:  M Virtala; J Kirveskari; K Granfors
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

3.  Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis.

Authors:  C Fendler; S Laitko; H Sörensen; C Gripenberg-Lerche; A Groh; J Uksila; K Granfors; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

4.  Long-term prognosis of reactive salmonella arthritis.

Authors:  M Leirisalo-Repo; P Helenius; T Hannu; A Lehtinen; J Kreula; M Taavitsainen; S Koskimies
Journal:  Ann Rheum Dis       Date:  1997-09       Impact factor: 19.103

Review 5.  Insights into the Role of Infection in the Spondyloarthropathies.

Authors:  Y Liu; M A Penttinen; K Granfors
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

6.  Infectious background of patients with a history of acute anterior uveitis.

Authors:  M Huhtinen; K Laasila; K Granfors; M Puolakkainen; I Seppälä; L Laasonen; H Repo; A Karma; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

7.  Comparison of rheumatological and gastrointestinal symptoms after infection with Campylobacter jejuni/coli and enterotoxigenic Escherichia coli.

Authors:  H Locht; K A Krogfelt
Journal:  Ann Rheum Dis       Date:  2002-05       Impact factor: 19.103

8.  Yersinia-specific antibodies in serum and synovial fluid in patients with Yersinia triggered reactive arthritis.

Authors:  O Mäki-Ikola; R Lahesmaa; J Heesemann; R Merilahti-Palo; R Saario; A Toivanen; K Granfors
Journal:  Ann Rheum Dis       Date:  1994-08       Impact factor: 19.103

9.  IgA1 and IgA2 subclass antibodies against Klebsiella pneumoniae in the sera of patients with peripheral and axial types of ankylosing spondylitis.

Authors:  O Mäki-Ikola; M Nissilä; K Lehtinen; M Leirisalo-Repo; K Granfors
Journal:  Ann Rheum Dis       Date:  1995-08       Impact factor: 19.103

Review 10.  Aetiology and pathogenesis of reactive arthritis: role of non-antigen-presenting effects of HLA-B27.

Authors:  Sanna Vähämiko; Markus A Penttinen; Kaisa Granfors
Journal:  Arthritis Res Ther       Date:  2005-05-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.